BACKGROUND
Perioperative chemotherapy is standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectab...
Aravind Sreeram, Celine Yeh, N. Toumbacaris et al.· The Oncologist· 0 citations
OBJECTIVE
We sought to compare pathologic responses, perioperative outcomes, and early survival between induction chemoradiotherapy and perioperative chemotherapy ± immunotherapy in patients with resectable esophageal adenocarcinoma.
METHODS
Using our prospectively maintained institutional database, we retrospectivel...
Aroub A. Alkaaki, Nian-Ye Zheng, N. Toumbacaris et al.· Journal of Thoracic and Card...· 0 citations
PURPOSE
Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to characterize the immune microenvironment of CLDN18.2-expressing gastric cancer and identify immune feature...
Joseph J. Zhao, Choong-kun Lee, Allison S. Y. Chan et al.· Clinical Cancer Research· 0 citations
Background Despite advances in perioperative and neoadjuvant strategies, patients with locally advanced gastroesophageal cancers remain at high risk of recurrence after curative intent treatment. No validated biomarkers are available to detect minimal residual disease (MRD) or to guide post-operative risk-adapted manag...
A. Puccini, L. Paracchini, R. Alfieri et al.· ESMO gastrointestinal oncolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.